Biolog Wins SBIR Grant to Develop Tox Applications for Mammalian Cell Arrays | GenomeWeb

First there were gene arrays, followed by protein arrays. Now, biotech firm Biolog is one step closer to commercializing the first living mammalian cell arrays for drug-discovery and -development applications.

The Hayward, Calif.-based company announced last week that it has received a $2.5 million Phase II SBIR grant from the National Institutes of Health to develop predictive toxicology assays for human and mouse cells on its Phenotype Microarray cellular array technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.